Genome-wide polygenic risk scores highlight those at risk of coronary artery disease, atrial fibrillation, type 2 diabetes, IBD, and breast cancer.
The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
Last week, GenomeWeb's readers were most interested in a lawsuit filed against Illumina, Thermo Fisher, and others, alleging trade secrets theft and fraud.
Researchers used WGS to diagnose the patients when previous testing couldn't find an underlying genetic cause for their symptoms.
Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.
The researchers distinguished histologic subtypes of appendiceal cancer and confirmed that it is distinct from colorectal and other GI cancers.
With genotyping data for more than 100,000 endometrial cancer cases and controls, researchers found nine new risk loci before delving into genes and pathways involved.
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
An international team of researchers also suggested that MUC16 mutations could identify patients who might benefit from immunotherapy treatment.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
With this model, the Geisinger team disclosed secondary genomic findings to 95 percent of the MyCode Community Health Initiative participants with such results.
By sequencing 72,501 individual kidney cells, researchers saw some shared transcriptional patterns in kidney cancers and developing or adult kidneys.
Researchers integrated results from a pathogen-host association study with available clinical data to find variants influencing both infection responses and other disease risks.
The company had previously said that it expected gross proceeds of up to $22.6 million if rights to all 25,000 securities units were exercised.
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.
The company posted Q2 revenues of $8.6 million, up from $5.2 million in Q2 2017 and above the consensus Wall Street estimate of $7.9 million.
Under a new partnership, Finnish DTC testing company Negen will send its raw genetic test data to BC Platforms to aid in reporting test results to clinicians.
The company intends to use the proceeds for, among other things, investigating the use of blockchain technology in medicine and biotechnology.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.